26 results
DEFA14A
VERV
Verve Therapeutics Inc
26 Apr 24
Additional proxy soliciting materials
7:56am
must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make
8-K
EX-1.1
VERV
Verve Therapeutics Inc
29 Nov 23
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
4:54pm
information (collectively with the pricing information set forth on Annex A, the “Pricing Disclosure Package”): a Preliminary Prospectus dated … the Shares on the terms set forth in the Pricing Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and sell Shares
DEFA14A
de6xrfozkuuc8b eu
28 Apr 23
Additional proxy soliciting materials
7:49am
8-K
EX-99.1
j6aajsuc 6r
7 Nov 22
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
7:00am
8-K
EX-1.1
p5zl6ogcythu0
21 Jul 22
Verve Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
4:46pm
DEFA14A
hdd5vhz5naustg
29 Apr 22
Additional proxy soliciting materials
7:22am
DEF 14A
edlpay2 pddeb39ni
29 Apr 22
Definitive proxy
7:01am
10-K
w7p8nuwjhhn9g2
14 Mar 22
Annual report
7:04am
424B4
653wycqv9a6l51ky
17 Jun 21
Prospectus supplement with pricing info
4:50pm
S-1/A
EX-1.1
6qoz9sgh 5qaeg3jk
14 Jun 21
IPO registration (amended)
6:15am
S-1/A
l5ofy
14 Jun 21
IPO registration (amended)
6:15am